With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.,50998-17-9
EXAMPLE 1; 6-[3-(Piperidin-l-ylmethvDphenyllquinoxalineA mixture of 6-bromoquinoxaline (42 mg, 0.2 mmol), 3-(piperidin-l-ylmethyl)- phenylboronic acid pinacol ester hydrochloride (67 mg, 0.21 mmol), 2M aqueous sodium carbonate solution (0.3 mL, 0.6 mmol) and Pd(PPh3 )4 (7 mg, 0.006 mmol) in DME (0.6 mL) was heated to 12O0C in a sealed tube, under microwave irradiation, for 20 minutes. After cooling, the mixture was partitioned between saturated ammonium chloride solution and EtOAc (2 mL each), and the organic phase concentrated in vacuo. The residue was purified by preparative HPLC to give the title compound (34 mg, 56%) as a pale yellow- brown gum. deltaH (CDCl3) 8.88 (d, IH), 8.85 (d, IH), 8.33 (d, IH), 8.19 (d, IH), 8.08 (dd, IH), 7.75 (s, IH), 7.68 (d, IH), 7.48 (t, IH), 7.41 (d, IH), 3.69 (s, 2H), 2.46-2.63 (m, 4H), 1.59-1.72 (m, 4H), 1.40-1.53 (m, 2H). LCMS (ES+) 304 (M+H)+, RT 2.49 minutes.
As the paragraph descriping shows that 50998-17-9 is playing an increasingly important role.
Reference£º
Patent; UCB PHARMA S.A.; BUeRLI, Roland; HAUGHAN, Alan, Findlay; MACK, Stephen, Robert; PERRY, Benjamin, Garfield; RAPHY, Gilles; SAVILLE-STONES, Elizabeth, Anne; WO2010/52448; (2010); A2;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider